海外の急性リンパ性白血病治療のベスト医師 — ページ3

オファー・スピルバーグ医師は、白血病などの血液がんを専門とする腫瘍血液専門医です。

• アスタ・メディカルセンターで診療
• 血液がんを専門とする腫瘍血液学の専門知識
• 急性リンパ性白血病に対する標的治療を提供

アヴィハイ・シモニ医師は、シェバ医療センターの骨髄移植部門のディレクターです。複雑な血液がんの治療を専門としています。MDアンダーソンがんセンターで専門フェローシップを修了しました。シモニ医師は、高リスク患者に対して同種および自家移植を行っています。テルアビブ大学の教授であり、血液学のチェアマンを務めています。

• Forbes誌による2025年および2026年のイスラエルのベストドクターに選出。
• 細胞療法と移植に関する250以上の科学論文を執筆。
• 白血病、リンパ腫、多発性骨髄腫に対するCAR-T細胞療法を提供。
• Newsweek誌による世界トップ10病院に選ばれたシェバ医療センターに勤務。

アブラハム・アヴィグドール博士は、シェバ医療センター血液学研究所の所長です。リンパ腫、CAR-T療法、複雑な血液がんの分野における世界的権威です。アヴィグドール博士は、イスラエル・リンパ腫ワーキンググループを設立しました。2026年にニューズウィーク誌によって世界第7位にランクされたクリニックの運営を支援しています。

• 血液腫瘍学および細胞療法に関する130以上の科学論文を執筆。
• リンパ腫および骨髄腫に対するCAR-T細胞療法の統合におけるパイオニア。
• 同種および自家骨髄移植プログラムを主導。
• イスラエル・リンパ腫研究グループの議長を務めた。

ヒラ・マゲン博士は、シェバ医療センターのイスラエルを代表する血液腫瘍内科医です。多発性骨髄腫およびアミロイドーシスユニットを率いています。マゲン博士は、複雑な形質細胞疾患および高リスク骨髄腫の治療を専門としています。彼女は、革新的なポイント・オブ・ケアCAR-T療法プログラムの主任研究員です。彼女の研究は、高度な免疫療法を日常の臨床ケアにもたらしています。

• 100以上の科学論文および骨髄腫に関する画期的な研究を執筆。
• MDアンダーソンがんセンターおよびアーカンソー大学医学部でフェローシップを修了。
• CAR-T細胞療法および骨髄移植を実施。
• 2026年にNewsweek誌により世界第7位にランクされたシェバ医療センターに勤務。

2018年にForbes誌から最高の医師の一人に選ばれたステペンスキー博士は、ハダッサ医療センターで3,500件以上の骨髄移植を行ってきました。

• 28 年 小児骨髄移植の専門分野での経験
• 小児の希少な血液がん疾患に注力
• 患者からは「命を移植する人」として知られている
• 小児血液学専門ユニットを率いる

アイリス・クヴェンツェル博士は、シェバ医療センターの小児血液腫瘍科医であり、骨髄移植の専門家です。エドモンド＆リリー・サフラ小児病院にて、ユーイング肉腫や骨肉腫などの小児肉腫を治療しています。クヴェンツェル博士は、複雑な小児がんに対して標的療法と細胞治療を統合した治療を行っています。また、テルアビブ大学医学部の教員も務めています。

• 小児患者に対する骨髄移植およびCAR-T細胞療法の専門家。
• Li-Fraumeni症候群や感受性遺伝子を含む、がんの遺伝的素因を研究。
• 幹細胞生物学および外科腫瘍学（HIPEC）に関する主要ジャーナルで論文を発表。
• 世界トップ10病院にランクされるシェバ医療センターに勤務。

エラド・ヤコビ博士は、イスラエルにおける小児CAR-T細胞療法のパイオニアです。シェバ医療センターの小児細胞療法センターを率いています。ヤコビ博士は、再発性および高リスクの小児白血病やリンパ腫の治療を専門としています。ジョンズ・ホプキンス大学および米国国立がん研究所でフェローシップを修了しました。

• シェバ医療センター先端バイオセラピーセンターの医療ディレクター。
• 小児血液腫瘍学に関する240以上の科学論文の著者。
• 小児科、小児血液学、腫瘍学の専門医認定を取得。
• CAR-T細胞療法と骨髄移植の統合を主導。

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

慢性リンパ性白血病（CLL）およびリンパ腫の分野で世界的に認められたリーダーであるボッシュ博士は、バルセロナのキロン病院（Hospital Quiron）にて新しい治療法と分子研究の先駆者として活躍しています。

• 第1相から第3相まで、80以上の臨床試験を主導
• NEJMやNature Medicineなどのトップジャーナルに100以上の研究を発表
• スペインのCLL研究グループおよび臨床試験を統括
• コロンビア大学がん遺伝学研究所での博士研究員経験

ハダッサ医療センター血液科部長 – ベン・イェフダ教授は、急性リンパ性白血病に対する遺伝子治療と骨髄移植のパイオニアです。

• ニューヨークのメモリアル・スローン・ケタリングがんセンターで研修
• ハダッサ医学部初の女性学部長
• 分子診断学と免疫学を専門とする
• 卓越した患者ケアに対して「Healing with the Heart」賞を受賞

ジラ・ザッカーマン教授は、ランバム医療センターで血液学および移植学を専門としています。

• 急性リンパ性白血病治療の専門家
• 血液疾患の移植学を専門とする
• 豊富な学術的および臨床的経験を持つ教授

エルケ・イェーガー教授は、Focus誌のランキングによるとドイツのトップ腫瘍内科医の一人であり、ノルトヴェスト病院の腫瘍内科・血液内科を率いています。

• 肉腫治療を専門とする
• 41 年 の腫瘍学における経験
• 腫瘍内科・血液内科部長

ノルトヴェスト病院血液内科部長、36 年の経験を持つヴァイドマン医師は、血液疾患治療を専門としています。

• 非ホジキンリンパ腫の症例に注力
• 豊富な学術的・臨床的背景を持つ教授
• 専門的な血液内科部門を統括

血液学の准教授で50以上の論文を発表。エレン医師はビルニ大学病院にて血液疾患を専門としています。

• イスタンブール教育研究病院にて血液学の専門研修を修了
• 欧州血液学会およびトルコ血液学会の会員
• 全国血液学会議にて若手研究者賞を受賞
• 国際的な患者の診察に対応できる英語力

アパク医師は小児血液腫瘍学を専門とし、_doctor_6792_年以上の経験を持ち、ビルニ大学病院にて急性リンパ性白血病に注力しています。

• 骨髄移植およびCAR-T細胞療法の専門家
• 小児腫瘍学に関する75の国際的な論文を執筆
• イスタンブール大学ジェラフパシャ校小児血液腫瘍学部長
• トルコ小児科学会およびトルコ思春期医学会会員

ファビオ・チチェリ教授は、サン・ラッファエーレ病院にて急性リンパ性白血病に対する細胞・遺伝子治療の先駆的な臨床試験を主導しています。

• 血液学・骨髄移植ユニット長
• 血液がんの臨床試験における主任研究員
• 180本以上の科学論文を発表
• 欧州血液骨髄移植学会（EBMT）会員

イタリア最大級の骨髄移植部門の責任者であるペッカトーリ博士は、サン・ラファエーレ病院で年間90件以上の同種移植を監督しています。

• 29 年 の血液学および骨髄移植における経験
• 白血病、骨髄腫、移植に関する70以上の研究の著者
• 急性白血病に対する同種移植を専門とする
• 欧州およびイタリアの移植学会の会員
• 複雑な症例を含む900件以上の治療実績

急性白血病および幹細胞移植の専門家であるオマイ教授は、トルコのトップ機関で 36 年 の血液学の経験を積んでいます。

• Emsey病院血液科部長
• 日本の三重大学医学部で分子血液学の研修を修了
• 血液疾患の治療に関する65本以上の科学論文を発表
• 自家および同種幹細胞移植の両方を実施